U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07169643) titled 'Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)' on Aug. 24.
Brief Summary: This is a national multicenter, randomized clinical trial to evaluate the the efficacy and safety of DP administration in patients on the liver transplant waiting list to reduce intraoperative red blood cell concentrate transfusion.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Liver Transplant; Complications
Intervention:
DRUG: Darbepoetin (DP)
Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been...